| Drug General Information |
| Drug ID |
D02UDJ
|
| Former ID |
DNC002629
|
| Drug Name |
D-Serine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Phase 4 |
[1],
[2]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C3H7NO3
|
| InChI |
InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/t2-/m1/s1
|
| InChIKey |
MTCFGRXMJLQNBG-UWTATZPHSA-N
|
| CAS Number |
CAS 312-84-5
|
| PubChem Compound ID |
|
| PubChem Substance ID |
4003, 588250, 626975, 829388, 839068, 7887195, 8143525, 8194408, 14747454, 15146420, 17405644, 24278008, 26718244, 26753645, 26753646, 43127470, 46392862, 46508200, 47811035, 47885661, 48110736, 49748509, 49846980, 50045910, 50096464, 50096469, 50106988, 50106989, 53778194, 56312452, 56313140, 56437651, 57318000, 80530258, 85756772, 87350321, 87575662, 87636300, 90341480, 92298581, 92303181, 92717308, 99213597, 99224311, 103060962, 103204181, 103822437, 104038215, 104349603, 117518385
|
| Target and Pathway |
| Target(s) |
NMDA receptor subunit NR1 |
Target Info |
Inhibitor |
[3]
|
|---|
| Glycine receptor alpha-1 chain |
Target Info |
Inhibitor |
[3]
|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Calcium signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Circadian entrainment
|
|
Long-term potentiation
|
|
Glutamatergic synapse
|
|
Alzheimer's disease
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Huntington's disease
|
|
Cocaine addiction
|
|
Amphetamine addiction
|
|
Nicotine addiction
|
|
Alcoholismhsa04080:Neuroactive ligand-receptor interaction
|
|
PANTHER Pathway
|
Huntington disease
|
|
Ionotropic glutamate receptor pathway
|
|
Metabotropic glutamate receptor group III pathway
|
|
Metabotropic glutamate receptor group I pathway
|
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
|
|
Reactome
|
EPHB-mediated forward signaling
|
|
Unblocking of NMDA receptor, glutamate binding and activation
|
|
CREB phosphorylation through the activation of CaMKII
|
|
Ras activation uopn Ca2+ infux through NMDA receptor
|
|
RAF/MAP kinase cascadeR-HSA-975298:Ligand-gated ion channel transport
|
|
WikiPathways
|
SIDS Susceptibility Pathways
|
|
Hypothetical Network for Drug Addiction
|
|
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
|
|
Spinal Cord Injury
|
|
BDNF signaling pathway
|
|
Alzheimers Disease
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4171). |
|---|
| REF 2 | ClinicalTrials.gov (NCT00215904) D-serine Adjuvant Treatment for Parkinson's Disease. U.S. National Institutes of Health. |
|---|
| REF 3 | Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. |
|---|
